Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Primary cutaneous large B-cell lymphoma of the legs - A distinct clinical pathologic entity treated with CD20 monoclonal antibody (Rituximab)
Autore:
Aboulafia, DM;
Indirizzi:
Virginia Mason Med Ctr, Div Hematol Oncol, Seattle, WA 98111 USA Virginia Mason Med Ctr Seattle WA USA 98111 Oncol, Seattle, WA 98111 USA
Titolo Testata:
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
fascicolo: 3, volume: 24, anno: 2001,
pagine: 237 - 240
SICI:
0277-3732(200106)24:3<237:PCLBLO>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Keywords:
primary cutaneous large B-cell lymphoma of; leg; non-Hodgkin's lymphoma; rituximab; monoclonal antibody; treatment;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
17
Recensione:
Indirizzi per estratti:
Indirizzo: Aboulafia, DM Virginia Mason Med Ctr, Div Hematol Oncol, 1100 9th Ave,POB 900 H14-HEM, Seattle, WA 98111 USA Virginia Mason Med Ctr 1100 9th Ave,POB 900 H14-HEM Seattle WA USA 98111
Citazione:
D.M. Aboulafia, "Primary cutaneous large B-cell lymphoma of the legs - A distinct clinical pathologic entity treated with CD20 monoclonal antibody (Rituximab)", AM J CL ONC, 24(3), 2001, pp. 237-240

Abstract

Primary cutaneous large B-cell lymphoma of the legs (PCLBLL) is most commonly diagnosed in the elderly, and is generally confined to the lower parts of one or sometimes both legs. Despite treatment with radiotherapy, relapses and extracutaneous involvement can occur, and unlike other low-grade cutaneous-B-cell non-Hodgkin's lymphomas (NHLs), the prognosis is variable, with an estimated 5-year survival rate of 58%. This report describes the case of an 81-year-old man who was diagnosed with PCLBLL. Staging evaluation didnot reveal NHL elsewhere. The patient declined recommendations to receive cytotoxic chemotherapy. Instead, he was treated with anti-CD20 monoclonal therapy (rituximab) and his cutaneous lesions completely regressed during a 16-week period. This report suggests that rituximab is a therapeutic optionfor those patients with PCLBLL who may not be good candidates to receive radiation therapy or chemotherapy. Long-term follow-up and greater experience with rituximab in a variety of clinical settings will ultimately determine the appropriate role of this costly, but relatively safe, antibody-based therapy for CD20+ expressing NHLs.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 09:37:41